American Lithium’s Falchani Pilot Plant Fully Commissioned and Operating

American Lithium reported that its Falchani lithium pilot plant in Lima is fully installed and operating, with semi-continuous bench testing achieving 88.7% average lithium extraction versus the 80.0% recovery assumed in its February 2024 PEA. The company plans to operate the plant continuously for more than three months, processing 6-10 tonnes of mineralization to validate the flowsheet at scale and support future feasibility work. Falchani's low-impurity mineralization is targeted to produce battery-grade lithium carbonate exceeding 99.5% purity, though project economics and commercialization remain subject to feasibility, permitting and financing risks.

Analysis

The recovery uplift is economically meaningful only if it survives continuous operation and is accompanied by consumables, energy, water, and residue-handling costs consistent with the prior economic study. A roughly nine-point recovery gain increases payable output per tonne by about 11% versus the base case, which can reduce unit fixed-cost absorption and potentially improve project NPV disproportionately; however, it does not resolve the larger pre-revenue developer discount: financing, permitting, execution, and lithium-price assumptions. The company’s multi-asset portfolio also means any valuation response may be diluted by capital demands across its Nevada lithium and Peruvian uranium assets.

Near term, LI is likely to trade as a technical-validation optionality vehicle rather than on a revised fundamental valuation. The key 1-3 month catalyst is independently interpretable, end-to-end continuous-run data—including reagent consumption, throughput stability, impurity rejection, carbonate specifications, and mass balance—not another commissioning update. A successful run could narrow the metallurgy risk discount relative to claystone peers such as LAC and IONR, while a failure on scaling crystallization/evaporation would likely be punished more severely than the current release is rewarded.

Contrarian view: the market may over-credit headline recovery because pilot-scale testing does not establish commercial operability or capital intensity. The most valuable output is not a higher recovery figure but evidence that the process avoids high-cost evaporation/reagent intensity and produces saleable material repeatedly; absent these data, there is no basis to underwrite a feasibility-study rerating. Over 6-18 months, Peru country risk and equity-financing availability may matter more to LI’s equity value than incremental metallurgical performance.

Key Decisions for Investors

• Do not chase LI on the release; treat it as a watch-list catalyst. Reassess after the continuous-run report, requiring disclosed throughput, full mass balance, reagent/energy intensity, battery-grade assay, and a timeline to feasibility work.
• For high-risk-resource sleeves, initiate only a small tactical LI position after continuous-run validation, sized as venture optionality and funded by a short in a diversified lithium-miners basket (LIT) rather than a single developer. Target a 2-4 month catalyst window; exit if continuous recovery falls below the prior economic-study assumption or management defers feasibility work.
• Prefer LAC or ALB exposure for lithium-price beta until LI demonstrates commercial cost parameters: those names offer operating/near-production asset backing, whereas LI remains most sensitive to financing dilution and project-development slippage.
• Set alerts for lithium carbonate price deterioration and any Peru permitting/community developments. A sustained lower-price environment or a discounted equity raise would outweigh a modest recovery improvement and falsify a near-term rerating thesis.